| |
| | [No title] |
 | | On a GAAP basis, Chiron's loss from continuing operations was $20 million, or $0.11 per share, for the third quarter of 2003, compared to income from continuing operations of $83 million, or $0.43 per share, for the third quarter of 2002. |
 | | About Chiron Chiron Corporation, headquartered in Emeryville, California, is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products that make a difference in people's lives. |
 | | Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop products from its platforms in proteins, small molecules and vaccines. |
| www.freeedgar.com /EdgarConstruct/Data/891092/03-3052/e16036ex99_1.txt (2760 words) |
|